Titelblatt der Nationalen Strategie für gen- und zellbasierte Therapien mit Symbolen für acht Handlungsfelder, kreisförmig um ein zentrales Motiv angeordnet.

National Strategy for Gene- and Cell-based Therapies

Gene- and cell-based therapies (GCT) offer promising approaches to treating previously incurable diseases and can support regenerative processes. The National Strategy for Gene- and Cell-based Therapies (National Strategy GCT) aims to promote patient well-being as well as the biotech location Germany. In a multi-stakeholder approach, the strategy connects actors from science, economy, politics, society, and patients and works on the implementation of concrete measures to accelerate the transfer of these therapies into healthcare.

Bundesministerin Bettina Stark-Watzinger erhält von Professor Christopher Baum die Nationale Strategie für gen- und zellbasierte Therapien. Im Hintergrund stehen Mitglieder der Arbeitsgruppe für ein Gruppenfoto.

Gene- and cell-based therapies

Gene- and cell-based therapies (GCTs) are key technologies for innovations in biomedical research and healthcare. They not only modify the disease or alleviate symptoms, but also directly address the genetic cause of the disease process. This opens up promising prospects for patients with severe and very rare diseases for which there is currently no treatment available.

The National Strategy GCT is being implemented in eight interactive topics for the development of gene- and cell-based therapies.

Moderation and working groups

In March 2023, the Federal Ministry of Education and Research (BMBF, which is now the Federal Ministry of Research, Technology and Space, BMFTR) commissioned the Berlin Institute of Health at Charité (BIH) to moderate the development process for the National Strategy GCT. The BIH also provides the interim administration office for the National Strategy GCT.

The measures of the National Strategy GCT include:

Creation and publication of the strategy document as well as initiation of the implementation of the measures proposed therein
the establishment and operation of the National Network Office for GCT
the regulatory advice
funding for projects and personnel
the entrepreneurship program GeneNovate
the GeneNovate Investors’ Day

The working groups discuss the various topics of the National Strategy GCT in detail, define the objectives of each topic and recommend specific measures for implementing the strategy.

Darstellung der Verbände und Interessenvertretungen, die am Runden Tisch der Nationalen Strategie beteiligt sind

Strategy Document

Find out more details about the National Strategy for Gene- and Cell-based Therapies in our Strategy Document.
Download, Pdf (3 MB)

Gene- and cell-based therapies

Moderation and working groups

Find out more details about the National Strategy for Gene- and Cell-based Therapies in our Strategy Document.